Botulinum toxin B in the treatment of craniofacial hyperhidrosis

Karlqvist, Mattias; Rosell, Karolina; Rystedt, Alma; Hymnelius, Kristina; Swartling, Carl

doi:10.1111/jdv.12278

Cited by 29 publications

(41 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The degree of improvement in DLQI for the included patients corresponded well to the results in other studies using Btx in hyperhidrosis . Furthermore, the DLQI results are comparable with the results in studies using biologic drugs in severe psoriasis…”

Section: Discussionsupporting

confidence: 84%

“…Our experience is that many women with postmenopausal hyperhidrosis are incorrectly considered to have VMS, and receive treatments including estrogen substitution, selective serotonin/noradrenalin reuptake inhibitors and acupuncture. Craniofacial hyperhidrosis is a physical, psychosocial and consequence‐related handicap which negatively affects life quality . Wet hair, eye irritation, running makeup, mist on glasses, shame and low self‐confidence are common, leading to avoidance and withdrawal from the social arena.…”

Section: Introductionmentioning

confidence: 99%

“…According to international guidelines, botulinum toxin (Btx) type A is the second‐line treatment for hyperhidrosis if local antiperspirants (aluminum and zirconium salts) fail or are inappropriate . Btx has a strong inhibitory effect on sweating . However, Btx type A injections in the forehead and central face may elicit undesirable local muscle weakness, especially in elderly women with less facial muscle volume.…”

Section: Introductionmentioning

confidence: 99%

“…However, Btx type A injections in the forehead and central face may elicit undesirable local muscle weakness, especially in elderly women with less facial muscle volume. This problem has partly been solved by using Btx type B, which has a weaker effect on muscles compared with Btx type A, but still has a strong sudomotor inhibition . Consequently, the effect/side‐effect profile is more advantageous for Btx type B when treating craniofacial hyperhidrosis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Cabreus¹,

Swartling

Rystedt³

2019

The Journal of Dermatology

View full text Add to dashboard Cite

Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Cabreus¹,

Swartling

Rystedt³

2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Hyperhidrosis affects up to 3% of the population . Secondary hyperhidrosis may be associated with infections, malignancies, endocrine or neurological diseases .…”

mentioning

confidence: 99%